UNSPSC 51385612: Diethylamine salicylate

This classification denotes an anti-inflammatory with the molecular formula C11H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V7PT38BJU, chemically known as 2-carboxyphenolate;diethylazanium but generally known as acetylsalicylic acid, which bears US NIH Compound Identifier 54678495. European Medicines Agency schedules diethylamine salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB43350 and SUB13573MIG.

As of Q4 2014, DIETHYLAMINE SALICYLATE remains the US FDA Preferred Term for this commodity. SMILES: CC[NH2+]CC.C1=CC=C(C(=C1)C(=O)O)[O-].

UNSPSC 51385612 Diethylamine salicylate is a Commodity code that in practice does not align with recent state and local procurement activity. The single recent opportunity tagged to this code—Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems—covers pharmaceutical products and medical equipment for community health support, not diethylamine salicylate specifically. The county is procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must submit bids electronically, include all shipping and delivery costs in their proposals, maintain workers' compensation and commercial general liability insurance, comply with E-Verify requirements, and agree to a two-year initial term with an optional one-year renewal and a three-month probationary termination period.

The code shows minimal recent activity and no pattern of repeat issuing bodies or geographic spread that would signal consistent procurement demand. The single Seminole County opportunity (IFB, response deadline July 26, 2023) does not support a characterization of state or local buying patterns under this commodity code. Business development teams should not pursue this code based on current market signals; the recent opportunity tagged to it appears to represent a mislabeling rather than genuine demand for diethylamine salicylate within state and local government procurement.